{"id":5946,"date":"2025-09-16T15:13:56","date_gmt":"2025-09-16T22:13:56","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=5946"},"modified":"2025-09-18T08:59:23","modified_gmt":"2025-09-18T15:59:23","slug":"beta-preserve","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/beta-preserve\/","title":{"rendered":"\u03b2ETA PRESERVE"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””]<\/p>\n

<\/div>\n

This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if teplizumab can work better than a placebo (a look-alike with no medicine in it) in helping people keep their blood sugar in a healthy range or use less mealtime insulin.<\/p>\n

The study will last approximately 84 weeks (1.5 years) and includes 32 study site visits. Participants will receive all study-related medical care at no cost and will be closely monitored by a doctor throughout the study.<\/p>\n

Ages 8-25 will be enrolled first, followed by 1 to 25-year-olds later in the study.<\/p>\n

Participant Eligibility<\/h3>\n

To join this study, participants must:
\n– Be 1 to 25 years of age. (Ages 8-25 will be enrolled first, followed by 1 to 25-year-olds later in the study.)
\n-Have been recently diagnosed (within a month) with T1D.
\n-Be positive for at least one T1D autoantibody (proteins that attack insulin-making cells by mistake).<\/p>\n

Other criteria may also apply. It\u2019s okay if participants don\u2019t know if they qualify\u2014the study doctor will tell them if they do.<\/p>\n

Contact<\/h3>\n

the BRI Outreach Team
\n(800) 888-4187<\/p>\n

\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nA Randomized, Double-blind, 2-arm, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)
\n<\/span><\/p>\n

Study ID:<\/strong> 20250884<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT07088068<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 08\/06\/2025<\/div>\n
End Date:<\/strong> 06\/06\/2028<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nSandra Lord, MD
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

Benaroya Research Institute<\/h4>\n

1201 Ninth Ave
\nSeattle, Washington 98101<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””] This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[968,1688,393,327,409,323],"class_list":["post-5946","post","type-post","status-publish","format-standard","hentry","category-diabetes","tag-beta-cells","tag-beta-preserve","tag-t1d","tag-t1dm","tag-teplizumab","tag-type-1-diabetes"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=5946"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5946\/revisions"}],"predecessor-version":[{"id":5948,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5946\/revisions\/5948"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=5946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=5946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=5946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}